Ex Vivo Expanded Autologous Immune Killer Cells (IKC)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Ex Vivo Expanded Autologous Immune Killer Cells (IKC), covering 2020-04-16 to 2020-04-16. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy [Phase 2]